The CURA Project also took the field on June 15 and called on the main superstars who are active in the attack against cancer. The dinner took place at the house of Dr Fernando Maluf, one of the CURA Ambassadors, was organized by the Director of CURA, Fernanda Schwyter and was attended by several specialists, members of the LACOG - Latin American Cooperative Oncology Group and big names in society, from different sectors, who were honoring this project and contributing to this cause, such as the singer Margarete Menezes, who was the godmother of the first dinner in favor of cancer research.
The Best of ASCO will take place on June 15 and 16 in the city of São Paulo. It is an official ASCO event in partnership with LACOG that aims to present the main studies from the American Congress in Brazil to oncologists who were unable to attend the event. Thus, ASCO provides the complete results and the slides of each study presented and invited professionals (both Brazilian and international) present the results, followed by a discussion of the studies. The Best of ASCO aims to disseminate the latest Oncology research to all Brazilian professionals. In this way, the population benefits indirectly, since more up-to-date and qualified oncologists can provide better treatments and thus improve cancer outcomes in Brazil.
Registrations for professionals in the field are FREE! The schedule can be found at this link.
From June 01 to June 5, 2018, the ASCO - American Society of Clinical Oncology will take place. This annual meeting (ASCO Annual Meeting) is always held in the month of June in Chicago, United States. It is considered the world's largest congress on Clinical Oncology, bringing together more than 30,000 doctors and health professionals from around the world. This event presents the results of the most important cancer studies, many of which have an impact on clinical practice.
Event website: https://am.asco.org/How will LACOG participate in ASCO 2018?Lacog will present 3 abstracts at this important event. Two abstracts refer to the EVITA study — an epidemiological study on cervical cancer in Brazil. This study is in progress (these publications were initial results of the research). This study was developed by LACOG in partnership with EVA (Brazilian Gynecological Tumor Group). The third abstract is a study developed by the GBOT (Brazilian Thoracic Oncology Group) in which LACOG supported the planning, analysis and writing of the results.What type of research was carried out?EVITA is an observational study that collected data from patients treated at their respective institutions. The study continues with the follow-up of patients to assess treatment, quality of life, and survival over time. The GBOT study, on the other hand, collected the results of pathology laboratory tests to assess the prevalence of pd-l1 marker positivity in lung tumors. This study is complete and we will be working on its publication.Were these studies conducted by LACOG member doctors?In the EVITA study, several LACOG researchers were included in their respective hospitals and clinics, comprising all Brazilian regions. All participating doctors are members of LACOG. The supervision, conduct of the study, data analysis and publication were carried out at the LACOG Office in Porto Alegre. The PD-L1 lung cancer study was conducted by a group of investment oncologists from GBOT/LACOG and pathologists from reference laboratories in Brazil. The database and statistical analysis were carried out at the LACOG office, which has personnel specialized in clinical research.What is the importance of these studies?The Cervical Cancer Study (EVITA) is the largest study ever conducted in Brazil on the disease. Its objectives are to characterize the patient population (age, age group, income, personal and family history, treatments performed), evaluate screening through the Pap smear (how many women did it, why didn't) and study the quality of life of these patients before and after treatment, using evaluation criteria from the EORTC (European Organization for Research and Treatment of Cancer). The 3 abstracts are available on the LACOG website, the last 3, dated as 2018. The following link is: http://lacog.org.br/publications
A study presented by the Ministry of Health shows that more than half of the young population in Brazil is infected with HPV.
These are data that attract attention: HPV is a virus that can cause various types of cancer, such as that of the cervix, penis, anus, and more recently it has been associated with throat cancer (tonsils and base of the tongue).
Throat cancer is most often associated with smoking and alcoholism. But that has changed in several countries around the world, with HPV being the main causative factor. In some countries in Europe and the USA, throat cancer caused by HPV is already considered an epidemic by some scholars. In Brazil, data show that most of these tumors are still related to tobacco and alcohol.
But that is changing. We currently have several patients with throat cancer caused by HPV even in Brazil.
What about the vaccine? Help? Will it lower the risk of this cancer?
Yes! The HPV vaccine prevents a person from becoming infected with the cancer-causing HPV viruses. If there's no infection — there's no cancer caused by the virus.
And is it effective at preventing infection?
Yes! At the American Oncology Congress this year, a study was presented that evaluated oral infection with the HPV virus after vaccination of young adults. The vaccine showed an efficacy of 88% {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in reducing the rate of oral cavity infection in vaccinated individuals.
Brazil has already incorporated the HPV vaccine into the national vaccination schedule. For girls in 2014 and for boys in 2017. However, the adherence rate to the vaccine is still insufficient.
Each of us has to do our part. The question IS CANCER CURABLE? — it should not be answered by doctors alone.
Each one of us has a responsibility to seek a cure for cancer: whether by taking proper care of the patient, researching, adopting healthy lifestyle habits and, FINALLY, VACCINATING AGAINST HPV.
Text prepared by Dr. Aline Chaves — member of LACOG
On the occasion of World Cancer Day (February 4), EORTC - European Organization for Research and Treatment of Cancer and BIG - Breast International Group, entities that support LACOG - CURA, prepared a press release with the objective of increasing awareness of male breast cancer.
Breast cancer is about 100 times less common in men than in women. Due to the rarity of this disease, it is normally excluded from clinical trials and doctors generally use the treatment applied to women. In new investigations carried out, the scientists demonstrated the feasibility of carrying out a therapeutic clinical trial in a rare patient population, which represents 1 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of all breast cancers. The American Cancer Society estimates that around 2,550 new cases of invasive male breast cancer will be diagnosed in the United States in 2018 and that around 480 men will die from this disease. For more information, click on this link: https://www.cancer.org/conte... /DAM/CRC/PDF/Public/8584.00.pdf
Now, CURA and the ARD Foundation joined forces to raise funds to fight cancer. Look forward to our calendar of events!
Because of World Cancer Day (February 4), the EORTC - European Organization for Research and Treatment of Cancer) and the BIG - Breast International Group, entities that support LACOG - CURA, prepared a press release with the objective of raising awareness about male breast cancer.
Recent findings from international breast cancer research confirm that the disease in men and women is undeniably different and that 1 in 3 men affected by the disease is not treated properly. Breast cancer is about 100 times less common among men than among women. Due to the rarity of the disease, they are generally excluded from clinical trials, and doctors generally use the treatment applied to women. In new research, scientists demonstrated the feasibility of pursuing a therapeutic clinical trial in a rare patient population, which represents 1 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of all breast cancers. American Cancer Society It is estimated that in the USA about 2,550 new cases of invasive male breast cancer will be diagnosed in 2018 and about 480 men will die from the disease. For more information, visit this link: https://www.cancer.org/conte…/dam/CRC/PDF/Public/8584.00.pdf
In these difficult days for the country and for public health, EXCELLENT NEWS: the incorporation, by the SUS, of PERTUZUMAB for the treatment of patients with HER2-positive metastatic breast cancer. This represents More LIVES with more QUALITY!!!
See the ordinance that makes the matter official:
Dr. Aline Chaves, an oncologist at LACOG, from the Head and Neck area. A study presented by the Ministry of Health shows that more than half of the young population in Brazil is infected with HPV. These are data that attract attention: HPV is a virus that can cause various types of cancer such as cervical cancer, penis, anus and more recently it has been associated with throat cancer (tonsils and base of the tongue). Throat cancer is most often associated with smoking and alcoholism. But that has changed in several countries around the world, with HPV being the main causative factor. In some countries in Europe and the USA, throat cancer caused by HPV is already considered an epidemic by some scholars. In Brazil, data show that most of these tumors are still related to tobacco and alcohol. But that is changing. We currently have several patients with throat cancer caused by HPV even in Brazil.What about the vaccine? Help? Will it lower the risk of this cancer?Yes! The HPV vaccine prevents a person from becoming infected with the cancer-causing HPV viruses. If there's no infection — there's no cancer caused by the virus.And is it effective at preventing infection?Yes! At the American Oncology Congress this year, a study was presented that evaluated oral infection with the HPV virus after vaccination of young adults. The vaccine showed an efficacy of 88% {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in reducing the rate of oral cavity infection in vaccinated individuals. Brazil has already incorporated the HPV vaccine into the national vaccination schedule. For girls in 2014 and for boys in 2017. However, the rate of adherence to the vaccine is still insufficient. Each one of us has to do our part. The question IS CANCER CURABLE? — it should not be answered by doctors alone.Each one of us has a responsibility to seek a cure for cancer: whether by taking proper care of the patient, researching, adopting healthy lifestyle habits and, FINALLY, VACCINATING AGAINST HPV.
On September 26th and 27/09, the Cura Project participated in another edition of the congress All Together Against Cancer in São Paulo. In addition to the stand, where people could learn more about CURA, on the 27th, the LACOG - Latin American Cooperative Oncology Group reflected on the situation of the cancer epidemic and described the benefits and ways of conducting a clinical study in Brazil. The panel “The Benefits of Research and Scientific Innovation in Oncology for Cancer Patients” brought together great specialists in oncology such as Dr. Carlos Barrios, Dr. Sergio Simon, Dr. Fabio Franke. In addition to them, we had the presence of Bob Chapman, representative of the American Cancer Society, the coordinator of the Cure Project, the psychologist Fernanda Schwyter, and the patient Ana Cristina Angrisano, who gave her testimony about participating in clinical research.
This was another opportunity to discuss and disseminate the importance of encouraging clinical research in Latin America.
On October 10, Salvador came together to fight breast cancer and help with clinical research.
The Magia Rosa show included a performance by the musician Luiz Caldas, organized by the Distribute Project, under the sponsorship of the AMO Clinic and Imagepat. The initiative brought the Soteropolitan audience to the Castro Alves Theater to dance and all proceeds will go to the Healing Project.
It was a beautiful party, full of energy, friends and engaged people, wanting to know more about how to fight cancer.
Among all the exciting moments, we had the presence of the Junior MMA champion Cigano, who officially received his Cura Ambassador diploma on the TCA stage.
We just have to thank everyone present, the Sharing Project and the sponsors, for their support and for the great encouragement of clinical research through the donation to the Cura Project.
The strength of a champion can teach you a lot about the fight against cancer!
Junior Dos Santos Almeida, born in Caçador, in the interior of Santa Catarina, moved to Salvador at the age of 18 to try for a better life. He started fighting at the age of 21, after meeting master Yuri Carlton, who introduced him to Jiu-Jitsu in 2005. In 2008, he joined the UFC and won against big names on his way. In 2011, Cigano won the champion belt against Cain Velasquez. The athlete sees difficult moments as just another obstacle in the struggle that is life! Check out the athlete's message: [embed] https://youtu.be/Wybeu1fZqEU[/embed]
Last July, the BEST OF ASCO Brazil event took place at the Renaissance hotel in São Paulo. The meeting included the most important topics discussed at the annual meeting of the American Society of Clinical Oncology, which took place in Chicago. Organized by the Latin American Cooperative Oncology Group (LACOG), the BEST OF ASCO Brazil included a parallel program for debates on the future of cancer treatment in Brazil and a diploma ceremony for the award of diplomas to the first CURA Ambassadors, who are Dr. Fernando Maluf and Dr. Sérgio Simon. The coordinator of the Cura Project, Fernanda Schwyter, presented the diplomas and commented on the importance of to join forces for integrated awareness-raising and fundraising for the network of supporters of the CURA Project, making the research projects developed by LACOG financially feasible.
The consolidation of research activity is one of the solutions to meet the needs of the population, particularly those that depend on the public health system, reducing discrepancies and facilitating access to the best treatments and contributing to the fight against the disease.About the CuraDR Ambassadors. Sérgio Simon has a doctorate in medicine from FMUSP, specializations in Hematology and Clinical Oncology. In addition, he is a member of ASCO, ESMO, SBOC; CEO and founder of GBECAM and Clinical Oncologist and founding partner of the São Paulo Oncology Center.
Check out an interview with Dr. Sérgio:
[embed] https://youtu.be/4YIV2-29Wkk[/embed]
Dr. Fernando Maluf has a doctorate in Urology from FMUSP and is a Clinical Oncologist. He is a member of the Executive Committee of LACOG - CURA, head of Clinical Oncology at the Antônio Ermírio de Moraes Oncology Center of Benedicência Portuguesa de São Paulo. Check out an interview with Dr. Maluf: [embed] https://youtu.be/r9s-uD2c07M[/embed]
Latin America is about to face a cancer epidemic. It is expected that for every 3 people 2 will be diagnosed with the disease in the coming years and there will be more than 1 million deaths annually, according to data from the World Health Organization (WHO), According to the doctor Carlos Barrios, executive director of the Latin American Cooperative Oncology Group - LACOG, one of the alternatives to face this dramatic increase in the number of cancer cases - which will be the leading cause of death in the coming decades -, is the consolidation of regional centers and groups of clinical research. “In Latin America, only 4 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of the global clinical studies in progress, according to surveys conducted by the National Institute of Health in the United States,” says the specialist. It is through research that knowledge is acquired about how the disease develops. The main barriers to the development of clinical research in Latin America include the lack of structure in national or regional organizations dedicated to cancer research, a limited number of qualified and specialized people (for example, statisticians, study supervisors, and other operational members), lack of public recognition of the importance of clinical research, legal and regulatory obstacles in some countries, and, critically, the lack of funding to support research. To address this problem, the CURA Project was born, a LACOG initiative. The Cura Project develops different actions, through music, art, design, sports and events to raise awareness, educate, and raise funds for scientific research in the fight against cancer. “Our intention is to make the population aware of the benefits of research, demystifying the fantasy that participating in studies is being a guinea pig. We want to show that RESEARCH SAVES LIVES! Research generates knowledge, research is treatment, in short, research is much more than we imagine. We need to mobilize society in relation to the topic and create a culture of financial contribution and engagement in scientific research,” he explains Fernanda Schwyter, coordinator of Cura.Read the full article in the Breast International Group magazine, which had its last edition entirely dedicated to Latin America and where you can learn more about the CURA PROJECT. https://www.slideshare.net/ProjetoCura/big-research-infocus-nmero-6-verso-em-portugus
Thank you for your collaboration in the fight against cancer. Associação Instituto Proyecto CuraCNPJ: 33.188.607/0001-04Banco Santander (Bank Code: 033) Branch: 0995 Current Account: 13.001.079-8
We are very grateful for your interest in learning about the Cure Project. If you can contribute with a donation in the future, we will be here waiting for your help:)
For credit card donations, we rely on the ease and security of the PayPal platform, which allows us to receive donations from the main national and international credit card brands. Click the button below and make a one-time or monthly donation. Help us fund research to cure cancer.
Thank you very much for the Donation.
HPV, a sexually transmitted disease caused by the human papillomavirus, is one of the main triggers of cervical cancer. Recently, however, HPV has also been identified as a cause of throat cancer.
The diagnosis can be made by the clinician or the otorhinolaryngologist, through physical examination and subsequent laryngoscopy. The best form of prevention is the HPV vaccine in addition, of course, to the safe practice of oral sex, taking some fundamental precautions such as the use of condoms, which also prevents the transmission of other diseases, including AIDS.
The main symptoms of throat cancer include:
Doubts? Consult your doctor.
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
There is a large gap between the emergence of new effective treatment options in oncology and their incorporation into the SUS. This means that our population does not benefit from medical advances in the same proportion as other countries that invest more in cancer treatment.What is Metastatic Breast Cancer?Metastatic breast cancer is an advanced stage of breast cancer in which the disease has spread to other organs. Although still incurable, the intense research activity on this topic provided great advances in this area, transforming it into a chronic disease (such as diabetes, for example, which is controlled with medicines).How is HER2-positive metastatic breast cancer treated?There are several types of breast cancer. Approximately 20 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} types of the disease are classified as HER2-positive. These tumors have a more aggressive clinical behavior, but great advances have been made in the last 2 decades. For example: according to statistics, with traditional chemotherapy alone the median survival of women is 20 months (1 year and 8 months). With chemotherapy associated with the drug TRASTUZUMAB, a specific antibody against the HER2 protein, this survival increases to 40 months (3.3 years). On the other hand, when treated with chemotherapy + TRASTUZUMAB + PERTUZUMAB (another antibody that also acts on the HER2 protein), the patient's life expectancy is 56 months (4.7 years).Do all HER2-positive breast cancer patients have access to these medications?No! Although there has been scientific evidence of the benefit of trastuzumab in advanced breast cancer since 2001, it has not yet been incorporated into the SUS.How to solve this?CONITEC, the National Commission for the Incorporation of Technologies into the SUS, is the body responsible for determining which treatments are provided by the Unified Health System. At present, there is a public consultation regarding the incorporation of TRASTUZUMAB and the TRASTUZUMAB + PERTUZUMAB “combo” for the treatment of HER2-positive breast cancer in the metastatic setting.HOW TO CONTRIBUTE?After reading the drug/technology technical report, citizens can make their suggestions and comments about the technology evaluated, as well as about the initial recommendation made by CONITEC. These contributions must be entered in the electronic form available on the portal. Participate! (Consultations 13 and 14)http://conitec.gov.br/consultas-publicas
After the high expectations raised regarding the efficacy of phosphoethanolamine in the treatment of cancer from the uncontrolled use of the substance in patients at USP São Carlos, the inclusion of new patients in research initiated in July 2016 was suspended due to lack of benefit. Of the 59 patients evaluated so far, only one, with melanoma, showed a response (there was an objective reduction in tumor size). The researchers conducting the study are now discussing whether the investigation will continue in patients with melanoma. By ethically and transparently testing a hypothesis, clinical research helps doctors and patients to discover what works (and what doesn't) in the treatment of cancer. Read more at: http://g1.globo.com/bemestar/noticia/fosfoetanolamina-instituto-do-cancer-suspende-testes-devido-a-ausencia-de-beneficio-clinico-significativo.ghtml
The AMAZONA III project is a collection of information about new cases of breast cancer in Brazilian women from 24 public and private health institutions, diagnosed as of January 2016, in the States of Amazonas, Bahia, Ceará, Goiás, Paraná, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul, Santa Catarina and São Paulo. Three thousand patients will be included, who will be followed up for 5 years after diagnosis.
The main objective of this study is to increase the knowledge of the medical community about this disease in the Brazilian population, considering socio-demographic characteristics, time of diagnosis, types of treatment and survival, with a view to identifying problems and solutions for the early diagnosis and treatment of breast cancer. This study is extremely important for Brazil because this type of neoplasm is the leading cause of cancer death in women in the world. Of the cases in the country, it is most common in the South (74.30/100 thousand) and Southeast (68.08/100 thousand), while its mortality is higher in the North and Northeast regions.
In an interview for the site Combating Cancer, Dr. Carlos Barrios - LACOG Executive Director - talks about the objectives of the Cura Project and the importance of epidemiological and therapeutic research. Check out: [embed] https://youtu.be/vkc2oUG9hro[/embed]
Latin American Cooperative Oncology Group (LACOG) and Breast International Group (BIG) launch a joint program with the participation of the EORTC for Latin American oncologists. With the program, oncologists from Brazil, Uruguay, and Peru must undergo a period of training in coordinating cooperative groups and conducting clinical studies. The experience should result in significant benefits in the development of clinical research in the area of Oncology in Latin America. Learn more: http://www.breastinternationalgroup.org/news/first-clinical-research-management-training-young-oncologists-latin-america/
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
